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Effects of L-2-oxоthiazolidine-4-carboxylic acid on the lung
antioxidant defense system in an asthma mouse model
Lyudmil GEORGIEV TERZIEV1, Veneta LYUBENOVA SHOPOVA2,Violeta YORDANOVA DANCHEVA2,
Galya TZVETANOVA STAVREVA3, Angelina MILCHEVA STOYANOVA4

Aim: We aimed to study the effect of a glutathione precursor, L-2-охоthiazolidine-4-carboxylic acid (OTCA), on the
lung antioxidant defense system in an animal asthma model.
Materials and methods: The study was carried out on 24 female C57BL/6 mice. The mice were divided into 4 treatment
groups: group 1 – control group; group 2 – injected with ovalbumin (OVA) and given an OVA inhalant; group 3 –
treated with OTCA and phosphate-buffered saline inhalant; and group 4 – injected with OVA and OTCA and given
an OVA inhalant. Under sodium pentobarbital anesthesia the animals were killed by exsanguination 48 h after the last
inhalation to obtain a lung homogenate. The activities of superoxide dismutase (SOD), catalase (CAT), and glutathione
peroxidase (GP) and the content of nonprotein sulfhydryl (NPSH) groups in lung homogenate were investigated.
Results: OVA decreased the activities of SOD (P = 0.007), CAT (P = 0.004), and GP (P = 0.05) and the NPSH content
(P = 0.0008) in the lung homogenate compared with the control animals. Treatment with OVA and OTCA (group 4)
resulted in a significant increase in the activities of CAT (P = 0.01) and GP (P = 0.05) and the NPSH content (P = 0.002)
compared to the OVA group (group 2).
Conclusion: OTCA (160 mg/kg) restored the activities of basic enzymes in the lung antioxidant defense system in an
OVA-induced asthma mouse model 48 h after the last nebulization.
Key words: Asthma, L-2-oхоthiazolidine-4-carboxylic acid, lung antioxidant defense system

Introduction
The development and maintenance of allergic
airway inflammation depends on the complex
interaction of many cytokines and chemokines. T
cells involved in the proallergic response produce
cytokines associated with induction of classical Th2
response, in which there is an oversecretion of IL4, IL-5, and tumor necrosis factor-α (TNF-α) (1).
Accompanied by an increase in the mortality rate
(2), bronchial asthma incidence has reached more
than 29% within the past years in the West European

countries (3). The development of an inflammatory
immune response in numerous pulmonary diseases,
including asthma, has been reported. It is described
as an activation of epithelial cells and macrophages
and an influx of activated neutrophils, eosinophils,
monocytes, and lymphocytes into the airways.
These cells can modulate the inflammatory response
known to form a large amount of reactive oxygen
species (ROS) and reactive nitrogen species (RNS)
in the airways (4,5). Enzymatic and nonenzymatic
antioxidants neutralize the toxic oxygen products
formed under physiological conditions. However,
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under conditions of oxidative stress, the balance
between oxidants and antioxidants is often disrupted
due to hyperproduction of ROS or depletion
of the antioxidant capacity (6,7). Glutathione,
synthesized from cysteine, is an important intraand extracellular protective antioxidant against
oxidative stress (8,9). The main protective roles of
glutathione against oxidative stress are: a) glutathione
is a cofactor of several detoxifying enzymes, such as
glutathione peroxidase and glutathione transferase;
b) it participates in amino acid transport through the
plasma membrane; c) it scavenges hydroxyl radical
and singlet oxygen, detoxifying hydrogen peroxide
and lipid peroxides by the glutathione peroxidase;
and d) it is able to regenerate the most important
antioxidants, vitamins C and E (10). Alterations in
alveolar and lung glutathione metabolism are widely
recognized as a central feature of many inflammatory
lung diseases, such as asthma. The antioxidant is
100 times more concentrated in the liquid covering
the respiratory epithelium than in the plasma (11).
It is now well established that L-2-oxothiazolidine4-carboxylic acid (OTCA) is a cysteine precursor
that increases the plasma cysteine and glutathione
concentrations (12,13). We aimed to study the effects
of OTCA on the antioxidant defense system in the
allergic mouse model.
Materials and methods
Chemicals
Ovalbumin (OVA; grade V), phosphate-buffered
saline (PBS), and OTCA were purchased from SigmaAldrich Company (USA), and Imject Alum® was
purchased from Pierce Chemical Company (USA).
Animals and experimental protocol
The experiment, performed in accordance with
regulations for animal welfare, was approved by the
university ethics committee.
The study was carried out on 24 female C57BL/6
mice weighing 20 ± 2 g at an age of 8-10 weeks old.
The animals were raised in the university’s animal
vivarium at a temperature of 22 ± 2 °C and humidity
of 50 ± 10%. They were given a normal pelleted diet
and water ad libitum. The mice were divided into 4
groups: group 1 – controls; group 2 – injected with
OVA; group 3 – treated with OTCA; and group 4
902

– treated with OVA and OTCA. The animals from
groups 1 and 3 were injected intraperitoneally on
days 0 and 14 with 100 μL of PBS and Imject Alum®
(1:1). The animals from groups 2 and 4 were injected
with a 100-μL OVA solution containing 20 μg of OVA
(p0012-protocol). On days 24, 25, and 26, mice from
groups 1 and 2 were given a PBS inhalant for 30 min,
and those from groups 2 and 4 were given a 1% OVA
solution (OVA dissolved in PBS). For this purpose,
a special Plexiglas chamber was used. One hour
before inhalation, the animals from groups 1 and 2
were injected intraperitoneally with 100 μL of PBS,
and those from groups 3 and 4 received 100 μL (160
mg/kg) of freshly prepared OTCA solution with pH
7.2. For all injections, individual sterile needles were
used.
Biochemical assays in lung homogenate
The animals were sacrificed on day 28 at 48 h after
the last inhalation. The chest was opened and the
lungs were perfused in situ via the right heart
ventricle with 10 mL of saline. The right lung was
ligated at the hilum, cut, and then removed from
the chest and used to prepare the lung homogenate.
The tissue was homogenized with ice-cold 0.25 M
sucrose in Tris HCl with pH 7.4 at a 1:10 ratio. The
homogenate was centrifuged (9000 × g, for 30 min)
and the supernatant was stored on ice. Superoxide
dismutase (SOD) activity in U/mg lung tissue was
determined by the method of Maral et al. (14), and
catalase (CAT) activity in mcat/g tissue was assessed
by the method of Koroljuk et al. (15). The activity of
glutathione peroxidase (GP) in U/g lung tissue was
measured by the method of Bernchnaider as modified
by Pereslegina (16). Nonprotein sulfhydryl (NPSH)
group content in mol/g tissue × 107 was measured by
the method of DeLucia et al. (17).
Statistical analysis
Experimental data were analyzed using SPSS 14.
When we tested for normality, 2 variables, GP and
CAT, showed nonparametric distribution, and we
used medians, interquartile ranges, and the MannWhitney test for comparison. For the rest of the
variables, we applied a post hoc ANOVA test, and
data are presented as mean ± standard error of
mean (SEM). P < 0.05 was considered statistically
significant.
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Results

Discussion

In group 2 (asthma-provoked), the activities of
SOD and CAT decreased significantly in the lung
homogenate by 71% (P = 0.007) and 77% (P = 0.004),
respectively, in comparison with the control animals.
The changes of SOD and CAT activities in group 3
(OTCA-treated) showed values close to the control
group: 96% and 98%, respectively. The results were
significant compared to the OVA group. The enzyme
activities of SOD and CAT in group 4 were lower: 78%
and 87% (P = 0.01), respectively (Table, Figures 1 and
2). Changes in GP activity showed a similar dynamic,
such as a decrease in the OVA group (68%) and
values approximate to those of the controls in group
4 (P = 0.05 in comparison to group 2) (Table, Figure
3). Nonprotein sulfhydryl (NPSH) group content in
the lung homogenate decreased in group 2 to 68% (P
= 0.0008), while in the group with OVA and OTCA
the decrease was relatively lower (93%, P = 0.002) as
compared to the OVA group (Table, Figure 4). The
GP activity and NPSH content in group 3 did not
differ significantly from those of the control group;
therefore, they were significantly higher compared to
group 2.

The experimental data of our study showed that
in mice, OVA can provoke asthma, a disease in
which oxidative stress and decreased antioxidant
capacity play a critical role (6). The activities of key
antioxidant enzymes such as SOD, CAT, and GP,
as well as NPSH content, decreased, suggesting an
antioxidant capacity disturbance. There are many
common assumptions concerning oxidative stress
in asthma. In exhaled breath condensate, the levels
of 8-isoprostane and CO are elevated, as well as the
activities of the enzymes GP and SOD in the lung cells
(18) and the products of peroxidation in the lungs,
serum, and urine. The content of malondialdehyde
and thiobarbituric acid reactive substances (TBARS),
as markers of lipid peroxidation, is elevated in
bronchoalveolar lavage fluid, urine, and sputum
(7,19). Alterations in alveolar and lung glutathione
metabolism are widely recognized as a central feature
of many inflammatory lung diseases, such as asthma,
in that either a decrease in liver glutathione stores or
impaired synthesis capacity is observed (20).

Table. Effect of OTCA on the activity of some enzymes of the lung antioxidant defense system in a mouse model of asthma.
28 days after treatment (48 h after the last inhalation)
Groups

Control

OVA

OTCA

OVA+OTCA

31.1 ± 1.79

22.1 ± 1.94*

29.9± 1.77

24.4 ± 2.75*

CAT activity in mcat/g
Median (min-max)
Q3-Q1

38.14
(33.08-44.12)
5.07

29.48*
(21.51-31.20)
4.30

37.42
(19.57-40.05)
8.14

33.14*†
(30.85-36.78)
3.37

GP activity in U/g
Median (min-max)
Q3-Q1

111.22
(51.40-138.74)
29.65

76.07*
(66.85-83.56)
6.38

125.97
(66.01-160.03)
66.14

101.53†
(63.96-122.43)
23.15

0.58 ± 0.03

0.40 ± 0.03*

0.55 ± 0.03

0.54 ± 0.007†

Parameters
SOD activity in U/g
Mean ± SEM

NPSH groups in mol/g × 10-7
Mean ± SEM

Abbreviations: OVA, ovalbumin; OTCA, L-2-oxothiazolidine-4-carboxylic acid; SOD, superoxide dismutase; CAT, catalase; GP,
glutathione peroxidase; NPSH groups, nonprotein sulfhydryl groups; SEM, standard error of mean; Q3-Q1, interquartile range.
*Different from control at P < 0.05; †different from group 2 (OVA) at P < 0.05.
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Figure 1. Activity of superoxide dismutase (SOD) in lung
homogenate (LH). Each point represents the mean ±
SEM for 6 mice.
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Figure 2. Activity of catalase (CAT) in LH. Each point represents
the median for 6 mice.

Content of NPSHin LH(mol/g ×10 -7)

Controls

P=0.004

0.7

P=0.0008

P=0.001

0.6

P=0.002

0.5
0.4
0.3
0.2
0.1
0

Controls

OVA

OTCA

OVA+OTCA

Figure 3. Activity of glutathione peroxidase (GP) in LH. Each
point represents the median for 6 mice.

Figure 4. Content of nonprotein sulfhydryl groups (NPSHs) in
LH. Each point represents the mean ± SEM for 6 mice.

The auspicious effects of OTCA on the
investigated enzymes of the antioxidant defense
system in the lungs can be explained by the fact that
OTCA is a cysteine precursor. This compound is
easily transportable into cells, where it is transformed
into L-cysteine, and glutathione is synthesized
from cysteine (8,9). OTCA, a 5-oxoproline
analog, is therefore a substrate for the ubiquitous
intracellular enzyme called 5-oxoprolinase (21,22).
5-Oxoprolinase catalyzes the reaction converting
5-oxoproline, also known as pyroglutamate, to
glutamate, which is required for the first step of
glutathione synthesis. The major nonenzymatic
scavenger is glutathione, which has been shown to
be an important component of the lung antioxidant
defense (23). It is unlikely to function as a direct
scavenger of H2O2, but it would rather serve as a
cofactor for peroxidases, such as the glutathione
peroxidase. OTCA can increase the plasma
concentrations of cysteine and glutathione (12,13),

thereby restoring the impaired balance between
oxidants and antioxidants (glutathione). OTCA is
more effective than N-acetylcysteine in replenishing
intracellular glutathione stores (24). In case of a
decrease in liver glutathione stores and impaired
synthesis capacity, OTCA can be successfully used
(20). It reduces the elevated levels of reactive oxygen
species (ROS), the increased expression of IL-18,
the inflammation of the airways, and bronchial
hyperreactivity in the animal asthma model (25). It
seems that the glutathione precursor may perform
its action by inhibiting the activity of nuclear factorkB (25-27).
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OVA provoked the development of asthma in the
mouse model, demonstrated by depletion of basic
antioxidant enzymes such as SOD, CAT, and GP, as
well as NPSH content in the lungs. OTCA, a cysteine
precursor, had a beneficial effect in the asthma mouse
model by increasing the glutathione concentrations.
OTCA administered intraperitoneally 1 h before
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nebulization with OVA on days 24, 25, and 26
restored the activities of basic enzymes CAT and GP
in the lung antioxidant defense system and NPSH
content 48 h after the last nebulization.
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